Our mission is to participate in world-leading & game-changing research that addresses the most pressing problems in GI cancers. We seek to identify specific situations where advances in science & technology intersect with current challenges in the clinical management of these cancers. Through multi-disciplinary collaborations, we aim to generate meaningful knowledge that lead to solutions that can effect dramatic improvements in patient outcomes.
Our approach is to sustain a comprehensive cohort of patients with serial tumor and blood samples collected across the patient’s journey with cancer to understand how the patient’s cancer changes spatiotemporally with treatment and time. We process patient samples in a manner compatible with the establishment of patient derived tumor models and isolate various components, e.g. immune cells, prospectively.
Detailed study description
Prospective observational cohort with prospectively processed samples optimal for biological interrogation
Prospective observational study:
Translational Research Priority Areas:
- Real-time diagnostics / biology /intervention, led by Dr. Iain Tan Bee Huat (MBBS, PhD):
Development of -omic informed therapeutic strategies e.g. neoantigen vaccines and ctDNA informed anti-metastatic therapy
- Tumor models, led by Dr Clarinda Chua Wei Ling (MBBS, MCI):
- Immunology, led by Dr Koo Si-Lin (MBBS, MMed):
- Onco-metabolomics & Patient reported outcomes, led by Dr Dawn Chong Qingqing (MBSS, MPH):
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Crescent, Singapore 169610 +65 6436 8000